RoMEA Pharmacogenetic Testing Market to 2032
Overview
The RoMEA Pharmacogenetic Testing Market is expected to reach a 13.83 USD Million by 2032 and is projected to grow at a CAGR of 4.86% from 2025 to 2032.
Revenue, 2024 (USD Million)
10.39
Forecast, 2032 (USD Million)
13.83
CAGR, 2024 - 2032
4.86%
Report Coverage
RoMEA
RoMEA Pharmacogenetic Testing Market 2018-2032 USD Million
RoMEA Pharmacogenetic Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 10.39 USD Million
- Projected Market Size (2032): 13.83 USD Million
- CAGR (2025-2032): 4.86%
Key Findings of RoMEA Pharmacogenetic Testing Market
- The RoMEA Pharmacogenetic Testing Market was valued at 10.39 USD Million in 2024.
- The RoMEA Pharmacogenetic Testing Market is likely to grow at a CAGR of 4.86% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Blood in Sample Segment accounted for the largest share of the market with a revenue of 6.03 USD Million
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 8.77% during the forecast period from 2024 to 2032.
RoMEA Pharmacogenetic Testing Market Scope
RoMEA Pharmacogenetic Testing Market Segmentation & Scope
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
RoMEA Pharmacogenetic Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 10.39 USD Million |
| Market Value in 2032 | 13.83 USD Million |
| CAGR (2025-2032) | 4.86% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Therapeutic Area,Sample,Drug,Application,Distribution Channel,End User,Gene,Type |
Regional Insights:
-
Leading Market (2024-2032): RoMEA, leading in terms of revenue 10.39 USD Million in 2024
- Key Country: RoMEA, leading in terms of revenue with value of 10.39 USD Million in 2024.
Segments and Scope
-
RoMEA Pharmacogenetic Testing Market to 2032, By Therapeutic Area
- Cardiology is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 2.15 USD Million in the year 2024.
- Cardiology is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 8.13 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By Sample
- Blood is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 6.03 USD Million in the year 2024.
- Blood is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 5.01 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By Drug
- Prescription Drugs is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 3.76 USD Million in the year 2024.
- Prescription Drugs is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 5.80 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By Application
- Clinical Practice is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 5.10 USD Million in the year 2024.
- Clinical Practice is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 5.27 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 5.12 USD Million in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 5.33 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By End User
- Healthcare Providers is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 4.64 USD Million in the year 2024.
- Healthcare Providers is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 5.45 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By Gene
- CYP2C19 is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 1.78 USD Million in the year 2024.
- CYP2C19 is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 8.77 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetic Testing Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in RoMEA Pharmacogenetic Testing Market to 2032 with a revenue of 5.36 USD Million in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in RoMEA Pharmacogenetic Testing Market to 2032 with a Growth rate of 5.32 % in forecast period 2025-2032.
RoMEA Pharmacogenetic Testing Market Company Share Analysis
| Company Name |
|
||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| QIAGEN | |||
| Sonic Healthcare Limited | |||
| BGI | |||
RoMEA Pharmacogenetic Testing Market Geographical Sales Distribution, 2018-2032 USD Million
RoMEA Pharmacogenetic Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The RoMEA Pharmacogenetic Testing Market is segmented based on Segmentation Therapeutic Area,Sample,Drug,Application,Distribution Channel,End User,Gene,Type.
RoMEA Pharmacogenetic Testing Market was valued at USD 10.39(Revenue in USD Million) in 2021.
RoMEA Pharmacogenetic Testing Market is projected to grow at a CAGR of 4.86% during the forecast period of 2024 to 2032.
The Blood segment is expected to dominate the RoMEA Pharmacogenetic Testing Market, holding a largest market share of 6.03 USD Million in 2024
RoMEA Pharmacogenetic Testing Market Scope
RoMEA Pharmacogenetic Testing Market Segmentation & Scope
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Frequently Asked Questions
The RoMEA Pharmacogenetic Testing Market is segmented based on Segmentation Therapeutic Area,Sample,Drug,Application,Distribution Channel,End User,Gene,Type.
RoMEA Pharmacogenetic Testing Market was valued at USD 10.39(Revenue in USD Million) in 2021.
RoMEA Pharmacogenetic Testing Market is projected to grow at a CAGR of 4.86% during the forecast period of 2024 to 2032.
The estimated market value of the RoMEA Pharmacogenetic Testing Market for final year is USD 13.83 (USD Million).
RoMEA Pharmacogenetic Testing Market Company Profiling
Frequently Asked Questions
The RoMEA Pharmacogenetic Testing Market is segmented based on Segmentation Therapeutic Area,Sample,Drug,Application,Distribution Channel,End User,Gene,Type.
RoMEA Pharmacogenetic Testing Market was valued at USD 10.39(Revenue in USD Million) in 2021.
RoMEA Pharmacogenetic Testing Market is projected to grow at a CAGR of 4.86% during the forecast period of 2024 to 2032.
The estimated market value of the RoMEA Pharmacogenetic Testing Market for final year is USD 13.83 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.